NPPA Orders Strict Monitoring of Revised Prices for 137 Anti-Cancer Drugs from November 9

NPPA Orders Strict Monitoring of Revised Prices for 137 Anti-Cancer Drugs from November 9

New Delhi, Nov 13: The National Pharmaceutical Pricing Authority (NPPA) has directed State Drug Controllers to intensify monitoring of revised prices for 137 non-scheduled anti-cancer medicines, ensuring that patients receive the full benefit of the government’s Trade Margin Rationalisation (TMR) initiative.

 Representational Image 

The revised prices came into effect on November 9, following a Gazette notification issued on October 17, 2026, by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers.

Manufacturers, hospitals told to display updated prices

The NPPA has instructed manufacturers, retailers, dealers, stockists, hospitals and medical institutions to strictly adhere to the revised maximum retail prices (MRPs).

They have also been asked to prominently display the latest price lists at their business premises and on their websites to ensure transparency and prevent patients from being charged more than the permitted rates.

The updated price lists, prepared on the basis of information submitted by pharmaceutical companies up to November 11, are available on the NPPA website and through the Pharma Sahi Daam app and portal.

State authorities asked to act against overcharging

State Drug Controllers have been directed to closely monitor manufacturers, medicine dealers, hospitals and medical institutions to verify compliance with the revised prices.

The authority has warned that violations could invite proceedings for overcharging under the provisions of the Drugs (Prices Control) Order, 2013.

State Drug Controllers have also been asked to submit their Action Taken Reports to the NPPA by November 16, 2026.

Patients can report complaints through helpline

Consumers can report complaints related to overcharging, shortages or non-availability of anti-cancer medicines through the Pharma Sahi Daam app or portal.

Complaints can also be registered through the NPPA helpline at 1800-111-255 or by email at monitoring-nppa@gov.in.

The monitoring exercise is aimed at ensuring effective implementation of the revised prices and preventing patients undergoing cancer treatment from facing additional financial burdens due to non-compliance.